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Subvalvular left ventricular aneurysm is a rare disease of obscure origin suggesting unique causes such as congenital, traumatic,
and inflammatory or infectious diseases. Its mortality is closely related to heart failure, mitral insufficiency, thromboembolic
phenomena, and cardiac arrhythmias. Although association with coronary artery disease is not described, the compression of
epicardial vessels by the aneurysm may lead to ischemic manifestations. We report here a case of mitral subvalvular left ventricular
aneurysm of probable chagasic origin, in a patient with normal left ventricular function evolving with repeated episodes of
monomorphic ventricular tachycardia, despite noninducible electrophysiological testing and the use of optimal medical treatment,
including amiodarone. The indication for implantable cardioverter-defibrillator in patients with Chagas cardiomyopathy and
segmental wall motion abnormalities but without global systolic dysfunction remains unclear in literature, even in the presence
of complex ventricular arrhythmias. A brief review of the literature on morphological features, diagnosis, prognosis, and treatment
will be also discussed.

1. Introduction
Mitral subvalvular left ventricular (LV) aneurysm is a rare
abnormality of unclear, likely varied, etiology. Suggested
origins include congenital defects, traumatic injuries, and
the sequel of inflammatory or infectious diseases [1, 2].
Similarly, the clinical manifestations, which include heart
failure, mitral regurgitation, thromboembolic phenomena,
and cardiac arrhythmias, are incompletely described in literature. Sudden death is among the rare reported presentations
of subvalvular LV aneurysms (both submitral and subaortic),
believed to be caused by direct coronary artery compression
by the aneurysm. Here, we present a case of mitral subvalvular

LV aneurysm in a patient with positive Chagas serology
and normal global systolic function evolving with repeated
episodes of monomorphic ventricular tachycardia (MVT),
refractory to oral amiodarone, despite no inducible complex
arrhythmias in electrophysiological (EP) testing.

2. Case Report
A 42-year-old Brazilian woman presented in 2010 to the
local emergency department (ED) with new-onset sustained
palpitations, hemodynamically stable and denying chest pain,
or dizziness. Her past medical history was negative for hospitalizations, trauma, major illness, or surgery. She took no
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Figure 1: (a) Baseline electrocardiogram, showing no atrioventricular or intraventricular conduction abnormalities, nor fragmenting of
the QRS complex. (b) Electrocardiogram performed in the emergency department showing monomorphic ventricular tachycardia with Rr’
pattern in V1, late R/S transition, and left axis deviation.

medications and had no known drug allergies. Electrocardiogram (ECG) revealed MVT, HR = 280 bpm, with Rr’ pattern
in V1, late R/S transition, and left axis deviation, suggesting
probable origin in the basal posterior inferior segment of
the LV (Figure 1). The patient received high-dose intravenous
(IV) amiodarone (300 mg), which ultimately converted the
MVT to normal sinus rhythm (NSR). The baseline ECG
(Figure 1) had neither atrioventricular or intraventricular
conduction abnormalities, nor other abnormalities such as
pathologic Q waves, low voltage, or QRS fragmentation.
She was discharged on oral amiodarone 600 mg/day. In 2011
the drug was discontinued and the patient was switched to
Atenolol 50 mg once daily. The patient was being managed by
the primary care physician and had not received cardiology
referral.
The patient remained asymptomatic in NSR until April
2012, when once more she was admitted to the ED with
palpitations, weakness, dizziness, and presyncopal symptoms. On physical examination the patient was diaphoretic,
hypotensive (BP 100/60 mmHg), and tachycardic (HR =
250 bpm). Again, ECG was consistent with MVT with the
same pattern as the index event, which again converted to
NSR with IV amiodarone.
Chest radiography was normal. Transthoracic echocardiography (TTE) revealed a subvalvular LV aneurysm (basal
portion of the inferolateral wall) with preserved LV systolic
function (LVEF = 65%), as confirmed later by ventriculography (Figure 2, Supplementary File in Supplementary Material available online at http://dx.doi.org/10.1155/2015/213104).
Treadmill stress test was negative for inducible ischemia.
Invasive coronary angiography was also normal (Supplementary File). Laboratory tests were positive for Chagas disease
(hemagglutination inhibition and indirect immunofluorescence). Electrophysiology testing failed to induce sustained
ventricular tachycardia after extensive endocardial and epicardial mapping: the programmed ventricular stimulation
protocol was conducted in two basic cycles (450 and 600 ms)
at the right ventricular apex and outflow tract with up to three
extra stimuli and finalized when the ventricular refractory
period or a minimum coupling of 200 ms was reached.
As no sustained ventricular tachycardia was induced, the

protocol was then repeated after infusion of Isoproterenol. No
evidence of epicardial circuit was found. The noninducibility was taken as a reassurance of benign prognosis (high
negative predictive value). At that point, electroanatomic
mapping (EAM) was not available in our institution. She did
not meet criteria for implantable cardioverter-defibrillator
(ICD)—in the attending heart-team’s point of view—and
was discharged from the hospital after one week on oral
amiodarone (800 mg/day, to be progressively reduced).
Despite good compliance with oral amiodarone, the
patient once again presented to our hospital in August 2013,
this time with hemodynamically unstable MVT. She was successfully converted to NSR with synchronized cardioversion.
Her echocardiogram remained unchanged, and no other
abnormalities were observed besides the mitral subvalvular
LV aneurysm. The patient was then referred to cardiology,
where the decision was made to go forward with ICD
implantation. The patient remains stable and asymptomatic
on oral Propafenone, with preserved LV function. She has not
had recurrence of her MVT and has never required any type
of therapy by her ICD after 2 years of device implantation.

3. Discussion
The present case illustrates a common dilemma on whether a
patient with Chagas cardiomyopathy without global systolic
dysfunction but with segmental wall-motion abnormalities
should maintain drug therapy or have ICD implanted after an
episode of sustained ventricular tachycardia without hemodynamic compromise. It also remarks the pattern of symptoms and short-term evolution of subvalvular LV aneurysm
evolving with repeated episodes of MVT in which the final
approach was ICD implantation.
Chagas disease affects approximately 20 million people
in Latin America. Cardiac involvement is the most serious
manifestation and accounts for more than 21,000 deaths every
year. The majority of these deaths result from heart failure
or sudden cardiac death secondary to malignant ventricular
arrhythmias [3].
Our case was also complicated by the presence of a
mitral subvalvular LV aneurysm, a rare cardiac abnormality
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Figure 2: Left ventriculography, showing the mitral subvalvular aneurysm: (a) right anterior oblique, end-diastole; (b) right anterior oblique,
end-systole; (c) left anterior oblique, end-systole.

first described in 1962 by Abrahams et al., thought to be
caused by a congenital defect in the posterior portion of
the mitral annulus and also by trauma, inflammatory, and
infectious diseases, and may produce symptoms through
diastolic overload [2, 4, 5], which has also been suggested as
an additional focus of arrhythmogenic substratum in patients
with Chagas disease [2, 4]. The mechanism of these arrhythmias is not always clear, but in some cases, compression of the
circumflex artery has been observed [1, 5]. In the current case,
the role of the subvalvular aneurysm is unclear, though we
presume it could have contributed to the refractoriness of her
ventricular arrhythmia. Indeed, while rare—Deshpande et al.
reported 16 cases (0.7%) of subvalvular aneurysms from 2,285
consecutive autopsies in 10 years [1]—subvalvular aneurysms
have been previously reported in patients with Chagas disease, sometimes associated with complex arrhythmias [2, 5].
In these cases, the probable arrhythmogenic substrate may
also include reentry in a scar derived from necrosis and
fibrosis caused by chronic inflammation of the myocardium.
The reentrant circuits can originate from subendocardial,
subepicardial, and intramyocardial injuries. For the latter,

intramural circuits may be kept by subepicardial fibers
[6].
The effectiveness of ICD for primary prevention of ventricular fibrillation (VF) and sustained VT for patients with
LVEF <35%, as well as for secondary prevention of VT/VF,
is well established [7] but primarily derived from data on
ischemic heart disease. More recently the ACCF/AHA/HRS
joint working group advocated for inclusion of other highrisk profile diseases, including Chagas cardiomyopathy, as
class IIa indications for ICD implantation. This recommendation is made without regard to ventricular function, given
the high risk of ventricular tachyarrhythmias in patients
with Chagas [3]. Moreover, for this case, these newer 2013
recommendations also put forward a IIa-C recommendation
for ICD in patients with sustained VT, regardless of hemodynamic significance [7]. Thus, our patient met two class II-a,
level of evidence C recommendations.
However, this case still presented a challenge in management, as the patient presented initially with signs of
good prognosis: no significant abnormalities (conduction
abnormalities, pathologic Q waves, and low-voltage) in
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baseline ECG, preserved LV systolic function with no significant structural cardiac disease, noninducible VT on
electrophysiologic study, and a good response to class III
antiarrhythmic medication. The positive Chagas serology was
only known after the second episode. Indeed, even if the
Chagas serology had been known, there is some debate if ICD
implantation prevents mortality in this population. Though
the total proportion of patients with Chagas disease was
low, a retrospective case review of patients with ventricular
tachycardia and normal LV function showed increased allcause mortality in patients treated with ICD plus antiarrhythmic drugs versus amiodarone alone [8]. Specifically
looking at a population with Chagas disease, Leite et al.
showed that, in a group of 150 patients with symptomatic VT
and moderate LV dysfunction, inducible hemodynamically
unstable VT was associated with higher mortality than both
inducible hemodynamically stable VT and noninducible VT
[9]. Contrasting this, data from patients that received ICD
for secondary prevention show that Chagas disease doubles
the risk of appropriate therapies and appropriate therapies
or death [10]. The sample, however, included mostly patients
with severe LV dysfunction, with functional impairment.
In a Latin American registry that included 89 chagasic
patients with ICD (91% for secondary prevention), 66% of
the individuals with LV dysfunction received therapy, while
only 18% of those with markers of good prognosis, such as
our patient, required any therapy. Moreover, compared to our
case the population was older (59 ± 10 years), 72% were male,
the mean LVEF was lower (40±11%), and most of the patients
were symptomatic [11].
Some doubts remain regarding substrate ablation in Chagas heart disease. It is known that the disease leads to slowly
progressive but incessant myocarditis, with widespread
destruction of myocytes, diffuse fibrosis, mononuclear cell
infiltration of the myocardium, and scarring of the conduction system [12, 13]. Thus, although the recurrence rate of
malignant ventricular arrhythmias seems to decrease with
the advent of EAM to establish the scar extension and
limits [4, 6], it is not uncommon for patients with good LV
function and favorable ablations to return 5 years afterwards
presenting LV dysfunction and recurrence of new sustained
ventricular tachycardias [6]. Recurrence rates are as high as
50% in some series [14], and current guidelines recommend
ablation (class I) only for incessant MVT or recurrent MVT
after ICD implantation [14]. In our case, it was not considered
at first due to the noninducibility during endocardial and epicardial stimulation protocols. After recurrences, EAM could
have been useful [4], but it was not available in our institution
and in most of the tertiary hospitals in Brazil, since the Public
Health System does not reimburse it. However, irrespective
of availability, EAM should not defer ICD implantation [6].
There is no robust data to support surgical ventriculectomy
in chagasic aneurysms [14], although there are some reports
of successful suppression of ventricular arrhythmias after
surgical repair of subvalvular aneurysms [15].
Given this case, we recommend routine testing for Chagas
in patients presenting with VT of unclear etiology who reside
in or have traveled to endemic areas. And we await more specific recommendations for indication of ICD in the context of
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primary prevention of sudden death in patients with Chagas
disease that will be answered by the on-going CHAGASICS
trial [16]. Though the data is still minimal, in the future we
would consider the presence of a subvalvular aneurysm in
a patient with Chagas disease an additional risk factor for
malignant ventricular arrhythmias—even in the absence of
global LV dysfunction—and consider this increased risk in
our decision-making regarding ICD placement.
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